Cholesterol and coronary heart disease

The 21st century

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Recent clinical trials have demonstrated that reductions of serum low- density lipoprotein (LDL) levels substantially decrease the risk for coronary heart disease. These trials confirm other lines of evidence that high levels of LDL are a critical atherogenic factor. Aggressive lowering of LDL levels in high-risk patients promises to significantly reduce morbidity and mortality from coronary heart disease in the first third of the 21st century. However, several additional measures will be required to marginalize coronary heart disease in the 21st century. Other lipoprotein abnormalities and other risk factors, eg, cigarette smoking, hypertension, and diabetes mellitus, must be controlled to obtain the full benefit of LDL-lowering therapy. Moreover, the health care delivery system must be reorganized to put more emphasis on prevention. Although much can be achieved through application of current knowledge in prevention efforts, further advances through new research will be required to remove coronary heart disease as a major cause of death in the United States.

Original languageEnglish (US)
Pages (from-to)1177-1184
Number of pages8
JournalArchives of Internal Medicine
Volume157
Issue number11
StatePublished - Jun 9 1997

Fingerprint

LDL Lipoproteins
Coronary Disease
Cholesterol
Delivery of Health Care
Lipoproteins
Cause of Death
Diabetes Mellitus
Smoking
Clinical Trials
Hypertension
Morbidity
Mortality
Serum
Research
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Cholesterol and coronary heart disease : The 21st century. / Grundy, Scott M.

In: Archives of Internal Medicine, Vol. 157, No. 11, 09.06.1997, p. 1177-1184.

Research output: Contribution to journalArticle

@article{39aa125860d149f8b86922666be7d34f,
title = "Cholesterol and coronary heart disease: The 21st century",
abstract = "Recent clinical trials have demonstrated that reductions of serum low- density lipoprotein (LDL) levels substantially decrease the risk for coronary heart disease. These trials confirm other lines of evidence that high levels of LDL are a critical atherogenic factor. Aggressive lowering of LDL levels in high-risk patients promises to significantly reduce morbidity and mortality from coronary heart disease in the first third of the 21st century. However, several additional measures will be required to marginalize coronary heart disease in the 21st century. Other lipoprotein abnormalities and other risk factors, eg, cigarette smoking, hypertension, and diabetes mellitus, must be controlled to obtain the full benefit of LDL-lowering therapy. Moreover, the health care delivery system must be reorganized to put more emphasis on prevention. Although much can be achieved through application of current knowledge in prevention efforts, further advances through new research will be required to remove coronary heart disease as a major cause of death in the United States.",
author = "Grundy, {Scott M}",
year = "1997",
month = "6",
day = "9",
language = "English (US)",
volume = "157",
pages = "1177--1184",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Cholesterol and coronary heart disease

T2 - The 21st century

AU - Grundy, Scott M

PY - 1997/6/9

Y1 - 1997/6/9

N2 - Recent clinical trials have demonstrated that reductions of serum low- density lipoprotein (LDL) levels substantially decrease the risk for coronary heart disease. These trials confirm other lines of evidence that high levels of LDL are a critical atherogenic factor. Aggressive lowering of LDL levels in high-risk patients promises to significantly reduce morbidity and mortality from coronary heart disease in the first third of the 21st century. However, several additional measures will be required to marginalize coronary heart disease in the 21st century. Other lipoprotein abnormalities and other risk factors, eg, cigarette smoking, hypertension, and diabetes mellitus, must be controlled to obtain the full benefit of LDL-lowering therapy. Moreover, the health care delivery system must be reorganized to put more emphasis on prevention. Although much can be achieved through application of current knowledge in prevention efforts, further advances through new research will be required to remove coronary heart disease as a major cause of death in the United States.

AB - Recent clinical trials have demonstrated that reductions of serum low- density lipoprotein (LDL) levels substantially decrease the risk for coronary heart disease. These trials confirm other lines of evidence that high levels of LDL are a critical atherogenic factor. Aggressive lowering of LDL levels in high-risk patients promises to significantly reduce morbidity and mortality from coronary heart disease in the first third of the 21st century. However, several additional measures will be required to marginalize coronary heart disease in the 21st century. Other lipoprotein abnormalities and other risk factors, eg, cigarette smoking, hypertension, and diabetes mellitus, must be controlled to obtain the full benefit of LDL-lowering therapy. Moreover, the health care delivery system must be reorganized to put more emphasis on prevention. Although much can be achieved through application of current knowledge in prevention efforts, further advances through new research will be required to remove coronary heart disease as a major cause of death in the United States.

UR - http://www.scopus.com/inward/record.url?scp=0030915254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030915254&partnerID=8YFLogxK

M3 - Article

VL - 157

SP - 1177

EP - 1184

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 11

ER -